DoW Melanoma Research Program Survivorship Research Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The fiscal year 2026 Melanoma Research Program Survivorship Research Award aims to advance the relatively underexplored field of melanoma-specific survivorship by funding innovative research focused on improving the quality of life, overall health, and functional well-being of melanoma survivors, their families, and care partners. Projects must move beyond animal models and survival metrics alone, incorporating broader survivorship outcomes. A mandatory element of the application is the inclusion of at least one melanoma consumer collaborator, such as a survivor, family member, care partner, or a melanoma community organization, to bring lived experience perspectives into the research process. Clinical trials are permitted under this award. Funding allocations total approximately $2.04 million, intended to support about two research awards, each with total costs capped at $1.02 million. The maximum period of performance for each award is three years. Funding is expected to be made using FY26 appropriations and will be disbursed no later than September 30, 2027, with funds expiring by September 30, 2032. The program is administered by the Department of the Army through the U.S. Army Medical Research Acquisition Activity under the Department of Defense, and inquiries can be directed to the provided contact resources.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Survivorship Research Award addresses the relatively new and underfunded area of melanoma-specific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors, their families and/or their care partners in the near term. Proposed studies focusing exclusively on animal models or considering survival only without consideration of quality of life, overall health and/or function are not responsive to this funding opportunity.
Distinctive Features:
· The application must include at least one melanoma consumer collaborator, defined as a melanoma survivor, family member and/or care partner who can provide lived experience expertise to the research project team, or a melanoma-community supporting organization to support the planning, execution, and implementation of the proposed research.
· Clinical trials are allowed.
Funding Details: The Congressionally Directed Medical Research Programs expects to allot roughly $2.04M to fund approximately two Survivorship Research Award applications with total cost caps of $1.02M per award. The maximum period of performance is 3 years. It is anticipated that awards made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.
https://cdmrp.health.mil/pubs/press/2026/mrppreann
